Skip to main content

Select Drug Profiles

Immunotherapy, Oncology

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

Immunotherapy, Oncology

Immunotherapy Combinations "Raising the Bar"

Breast Cancer, Oncology

Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer

Breast Cancer, Oncology

First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer

IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer

Breast Cancer, Oncology

Chemotherapy Can Be Spared in Many Patients with Early Breast Cancer: Devil Is in the Details

Breast Cancer, Oncology

CAR T-Cell Therapy Yields Impressive Responses in Aggressive Non-Hodgkin Lymphoma

Lung Cancer, Oncology

NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer

Multiple Myeloma, Oncology

Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma

Original Research, Practice Management

The Prevalence and Payer Costs of Potentially Avoidable Emergent Care Visits for Suspected Amniotic Membrane Rupture in Pregnant Women

Christine Ferro, CHFP, Bruce S. Pyenson, FSA, MAAA, Jocelyn Lau, MPH, Mona Kelkar, MBA, Nancy Phillips, MD, Chi-Wei Lu, PhD, Percy Yeung, PhD, Gloria Bachmann, MD

Christine Ferro, CHFP; Bruce S. Pyenson, FSA, MAAA; Jocelyn Lau, MPH; Mona Kelkar, MBA; Nancy Phillips, MD; Chi-Wei Lu, PhD; Percy Yeung, PhD; Gloria Bachmann, MD

Stakeholder Perspective

Interventions to Reduce Avoidable Pregnancy-Related Emergency Department Visits

Eliza Ng, MD

by Eliza Ng, MD

Page 69 of 244
Results 681 - 690 of 2434